medigraphic.com
ISSN 2007-3178 (Print)
Asociación Mexicana de Cirugía Bucal y Maxilofacial, Colegio Mexicano de Cirugía Bucal y Maxilofacial, A.C.

2020, Number 2-3

<< Back Next >>

Rev Mex Cir Bucal Maxilofac 2020; 16 (2-3)

Update on COVID-19 and possible management of its severe systemic complications with mesenchymal stem cells

López LJC, Acosta BC, López NJC

Language: Spanish
References: 53
Page: 61-70
PDF size: 213.29 Kb.


ABSTRACT

The progression of COVID-19 infection to an acute respiratory failure syndrome (SIRA-CoV-19) depends on the hyper activation of the immune system in order to eliminate the virus, which produces an exaggerated inflammatory response known as, "cytokine storm", initially affecting the lung; if it is not controlled, will cause cytokinemia, multiple organ failure, and death. This response is considered immunopathological due to its cyclical and inflammatory capacity, generating a vicious circle, which is characterized by an increase in the production of pro-inflammatory factors. Among the therapeutic properties of mesenchymal cells, its immunomodulatory and anti-inflammatory properties stand out. It has been shown that they can have a significant effect in preventing or decreasing cytokine storm through the secretion of potent anti-inflammatory substances and regulating the pulmonary inflammatory response. Thus decreasing the need for assisted mechanical ventilation and reducing patients in intensive care units.


REFERENCES

  1. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020; 10 (2): 102-108.

  2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-1062.

  3. https://www.cidrap.umn.edu/covid-19/epidemiology

  4. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/

  5. Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA, Zárate-Rojas E, Villalpando S, Barrientos-Gutiérrez T. Prevalencia de diabetes por diagnóstico médico previo en México. Salud Publica Mex. 2018; 60 (3): 224-232.

  6. Rivera Dommarco JA, Hernández Ávila M, Aguilar Salinas CA, Vadillo Ortega F, Murayama Rendón C. La obesidad en México. México: Instituto Nacional de Salud Pública; 2020.

  7. Cossarizza A, De Biasi S, Guaraldi G, Girardis M, Mussini C; Modena Covid-19 Working Group (MoCo19)#. SARS-CoV-2, the virus that causes COVID-19: cytometry and the new challenge for Global Health. Cytometry A. 2020; 97 (4): 340-343. doi: 10.1002/cyto.a.24002.

  8. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020; 11 (2): 216-228.

  9. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203 (2): 631-637.

  10. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020; 2020.01.31.929042.

  11. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician. 2020; 23 (2): E71-E83.

  12. Subramaniam S, Scharrer I. Procoagulant activity during viral infections. Front Biosci (Landmark Ed). 2018; 23: 1060-1081.

  13. van Gorp EC, Suharti C, ten Cate H, Dolmans WM, van der Meer JW, ten Cate JW et al. Review: infectious diseases and coagulation disorders. J Infect Dis. 1999; 180 (1): 176-186.

  14. Key NS, Vercellotti GM, Winkelmann JC, Moldow CF, Goodman JL, Esmon NL et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci U S A. 1990; 87 (18): 7095-7099.

  15. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-1720. doi: 10.1056/NEJMoa2002032.

  16. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020; 127: 104362.

  17. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020; 92 (4): 441-447. doi: 10.1002/jmv.25689.

  18. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109: 102433. doi: 10.1016/j.jaut.2020.102433.

  19. Wang L, Zou A, Wang J et al. Matrix analysis of clinical characteristics and dynamic observation of immunological features in 90 cases of COVID-19. SSRN 2020, published online April 02. 10.2139/ssrn.3556688 [preprint].

  20. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013; 13 (9): 752-761.

  21. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348 (20): 1986-1994.

  22. Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH, Wu A et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology. 2003; 228 (2): 401-406.

  23. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20 (4): 425-434.

  24. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 - A systematic review. Life Sci. 2020; 254: 117788.

  25. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP et al. Electronic address: https://www.lancovid.org. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020; 34: 101623.

  26. Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020; 95: 304-307.

  27. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020; 55 (5): 105955.

  28. Abbasi-Oshaghi E, Mirzaei F, Farahani F, Khodadadi I, Tayebinia H. Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. Int J Surg. 2020; 79: 143-153.

  29. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020; 27 (5): 1451-1454.

  30. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130 (5): 2620-2629. doi: 10.1172/JCI137244.

  31. Pambuccian SE. The COVID-19 pandemic: implications for the cytology laboratory. J Am Soc Cytopathol. 2020; 9 (3): 202-211.

  32. Zhang K, Liu X, Shen J, Li Z, Sang Y, Wu X et al. Clinically applicable ai system for accurate diagnosis, quantitative measurements, and prognosis of COVID-19 pneumonia using computed tomography. Cell. 2020; 182 (5): 1360.

  33. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020; 20 (5): 269-270. doi: 10.1038/s41577-020-0308-3.

  34. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8 (4): 420-422.

  35. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506.

  36. Hoogduijn MJ, Roemeling-van Rhijn M, Engela AU, Korevaar SS, Mensah FK, Franquesa M et al. Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev. 2013; 22 (21): 2825-2835.

  37. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transplant Proc. 2007; 39 (2): 573-576.

  38. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009; 18 (5): 683-692.

  39. Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev Rep. 2020; 16 (3): 427-433.

  40. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013; 143 (6): 1590-1598.

  41. Krampera M. Mesenchymal stromal cell ‘licensing’: a multistep process. Leukemia. 2011; 25 (9): 1408-1414.

  42. Blander JM. The many ways tissue phagocytes respond to dying cells. Immunol Rev. 2017; 277 (1): 158-173.

  43. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013; 13 (4): 392-402.

  44. Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe WE et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells. 2013; 31 (9): 1980-1991.

  45. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99 (10): 3838-3843.

  46. Liang B, Chen J, Li T, Wu H, Yang W, Li Y et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine (Baltimore). 2020; 99 (31): e21429.

  47. Mesoblast. Fase 2/3 ensayo controlado aleatorio de remestemcel-L en 300 pacientes con síndrome respiratorio agudo covid-19 comienza la inscripción. Melbourne, Australia; 30 de abril de 2020; y Nueva York, Estados Unidos; 29 de abril de 2020.

  48. https://www.cleveland19.com/2020/05/04/university-hospitals-cleveland-biotech-company-athersys-team-up-covid-clinical-trial/ (buscado el 11 de mayo de 2020)

  49. Guenther Koehne, M.D., Ph.D., and Javier Pérez-Fernández, M.D., safely administered the new treatment to patients through intravenous infusions of experimental umbilical cord mesenchymal stem cells. Clinical trial being conducted under an emergency approval from the Food and Drug Administration (FDA), Baptist Health Hospitalof Miami. May 4, 2020.

  50. https://pipelinereview.com/index.php/2020031374023/DNA-RNA-and-Cells/Pluristem-and-Charite-University-of-Medicine-Berlin-Join-Forces-Targeting-Potential-Treatment-for-Respiratory-and-Inflammatory-Intratissue-Complications-Caused-by-COVID.html. (buscado el 17 de marzo de 2020)

  51. FDA Approval to Commence First Mesenchymal Stem Cell Clinical Trial for Protection Against COVID-19. Houston, TX, April 06, 2020-Hope Biosciences.

  52. Qu W, Wang Z, Hare JM, Bu G, Mallea JM, Pascual JM et al. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020; 9 (9): 1007-1022.

  53. www.clinicaltrials.gov




2020     |     www.medigraphic.com